Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019
First evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019Continued […]